Patents by Inventor Markus KUGLER

Markus KUGLER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES TARGETING BONE MORPHOGENETIC PROTEIN 9 (BMP9) AND METHODS THEREFOR
    Publication number: 20190153084
    Abstract: The present invention relates to isolated antibodies and antigen-binding fragments thereof which bind human BMP9 and compositions and methods of use thereof.
    Type: Application
    Filed: July 5, 2018
    Publication date: May 23, 2019
    Applicant: NOVARTIS AG
    Inventors: Zijun Chen, Sujun Deng, Yun He, Dagang Huang, Markus Kugler, Qian Li, Chris Xiangyang Lu, Xiao Luo, Yongqiang Shan, Kathrin Ulrike Tissot-Daguette, Jing Wu
  • Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor
    Patent number: 10047155
    Abstract: The present invention relates to isolated antibodies and antigen-binding fragments thereof which bind human BMP9 and compositions and methods of use thereof.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: August 14, 2018
    Assignee: NOVARTIS AG
    Inventors: Zijun Chen, Sujun Deng, Yun He, Dagang Huang, Markus Kugler, Qian Li, Chris Xiangyang Lu, Xiao Luo, Yongqiang Shan, Kathrin Ulrike Tissot-Daguette, Jing Wu
  • ANTIBODIES TARGETING BONE MORPHOGENETIC PROTEIN 9 (BMP9) AND METHODS THEREFOR
    Publication number: 20160355583
    Abstract: The present invention relates to isolated antibodies and antigen-binding fragments thereof which bind human BMP9 and compositions and methods of use thereof.
    Type: Application
    Filed: May 26, 2016
    Publication date: December 8, 2016
    Applicant: NOVARTIS AG
    Inventors: Zijun CHEN, Sujun DENG, Yun HE, Dagang HUANG, Markus KUGLER, Qian LI, Chris Xiangyang LU, Xiao LUO, Yongqiang SHAN, Kathrin Ulrike TISSOT-DAGUETTE, Jing WU
  • Trispecific Therapeutics Against Acute Myeloid Leukaemia
    Publication number: 20120328619
    Abstract: The present invention relates to a molecule having binding specificities for (a) CD123; (b) CD16 and (c) CD33. The present invention further relates to the molecule of the invention, wherein the molecule comprises a first immunoglobulin domain comprising a VL domain linked to a VH domain, wherein the immunoglobulin domain specifically binds to CD123; a second immunoglobulin domain comprising a VL domain linked to a VH domain, wherein the immunoglobulin domain specifically binds to CD16; and a third immunoglobulin domain comprising a VL domain linked to a VH domain, wherein the immunoglobulin domain specifically binds to CD33. The present invention furthermore relates to a nucleic acid molecule encoding the molecule of the invention. In addition, the present invention relates to diagnostic and pharmaceutical compositions and the use of the molecule or the nucleic acid molecule of the invention in the treatment of acute myeloid leukaemia and/or myelodysplastic syndrome.
    Type: Application
    Filed: December 9, 2010
    Publication date: December 27, 2012
    Inventors: Georg H. Fey, Christoph Stein, Christian Kellner, Markus Kügler